Genentech's GDC-1261 Study Targets Advanced Prostate Cancer Safety and Activity
Genentech is conducting a study to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-1261 in advanced or metastatic prostate cancer.
Phase III
Oncology / Prostate Cancer
Status
Active
Sponsor
Roche
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing trial of GDC-1261 by Genentech is significant as it targets advanced prostate cancer, a critical area in oncology. Positive outcomes could enhance Genentech's competitive positioning and influence treatment options in a crowded market.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include the identification of recommended doses and regimen, as well as preliminary activity results.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.